Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitors and ARBs reduce mortality in heart failure with reduced ejection fraction
Hfref · ACEARB-HFREF-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The question is whether two families of blood-pressure drugs, ACE inhibitors and ARBs, help people with a weak heart live longer. Two older placebo-controlled trials of the ACE inhibitor enalapril found fewer deaths on the drug than on placebo [1][4]. For ARBs, a trial of candesartan against placebo also found fewer deaths [13], and a separate trial showed the ARB valsartan matched an ACE inhibitor on survival after a heart attack [3]. Several large real-world studies of patients treated in routine care point the same way [22][24][8]. The main reservations are that the direct ARB-versus-placebo evidence comes from essentially one drug programme and the ACE inhibitor trials were run decades ago on older background care, so the picture is fuller for ACE inhibitors than for ARBs.
Two independent double-blind placebo-controlled trials of enalapril in reduced-ejection-fraction heart failure show lower mortality than placebo: SOLVD reports 35.2% versus 39.7% with a 16% risk reduction [1], and CONSENSUS reports six-month mortality of 26% versus 44% in severe disease [4]. For the ARB limb, CHARM found all-cause mortality of 28.0% on candesartan versus 31.0% on placebo (HR 0.88, 95% CI 0.79 to 0.98) [13], while VALIANT showed valsartan non-inferior to the ACE inhibitor captopril on death from any cause after myocardial infarction [3]. A SOLVD post-hoc analysis found lower risk of a heart-failure-hospitalisation-or-death composite at both doses of enalapril [12]. Large cohorts in older adults [22], at hospital discharge [24], and in elderly Korean patients [8] associate renin-angiotensin inhibition with lower mortality. The contested point: The division is over how evenly the two drug classes are supported. Direct ARB-versus-placebo mortality evidence rests essentially on the single CHARM programme, where the effect is modest and barely significant (HR 0.88, P=0.018) [13], whereas VALIANT [3] is a non-inferiority trial in a post-infarction rather than chronic heart-failure population and carries no placebo arm. The ACE inhibitor limb has two independent placebo-controlled trials [1][4], so the ARB side is the thinner leg.
All 27 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Direct ARB-vs-placebo all-cause mortality rests essentially on a single programme (CHARM [13], HR 0.88 with lower CI 0.79-0.98 — modest and barely significant, P=0.018); VALIANT [3] is a post-MI noninferiority trial with no placebo arm, so the ARB limb of the claim is more thinly supported than the ACEi limb.
The large observational effect sizes [22][24][8] are vulnerable to confounding by indication and healthy-adherer bias; they corroborate direction but cannot carry the causal mortality claim on their own.
Where it remains uncertain. The direct ARB-versus-placebo signal comes from essentially one programme and is modest (HR 0.88, P=0.018 [13]), while VALIANT is a post-MI non-inferiority trial without a placebo arm [3].
Aleatory
The ARB all-cause mortality result sits close to chance with HR 0.88, upper CI 0.98 and P=0.018 [13], so the play of random variation is non-trivial for the ARB limb.
Epistemic
The ACE inhibitor trials show benefit on 1980s-90s conventional therapy [1][4]; the corpus holds no placebo-controlled test on contemporary beta-blocker, MRA, ARNI or SGLT2 backgrounds.
Inferential
VALIANT [3] is a post-myocardial-infarction non-inferiority trial, so extending its ARB-equals-ACEi result to chronic HFrEF is an inference beyond its enrolled population.
The load-bearing papers from a corpus of 27, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Landmark RCT establishing ACEi (enalapril) reduces all-cause mortality vs placebo in HFrEF.
“There were 510 deaths in the placebo group (39.7 percent), as compared with 452 in the enalapril group (35.2 percent) (reduction in risk, 16 percent; 95 percent confidence interval, 5 to 26 percent; P = 0.0036).”
Panel auditInternal validity: high · scope of inference: Chronic HF patients, EF <=0.35, mostly NYHA II-III, on conventional therapy of the era.Key limitations: ACE inhibitor only, no ARB arm · background therapy predates beta-blockers/MRAs
Demonstrates an ARB is noninferior to an ACEi on all-cause death, extending the class benefit to ARBs.
“Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction.”
Panel auditInternal validity: high · scope of inference: Patients 0.5-10 days after acute MI complicated by LV systolic dysfunction, HF, or both.Key limitations: post-MI population, not stable HFrEF · no placebo arm · head-to-head design
Independent RCT confirming ACEi mortality benefit in severe (NYHA IV) CHF.
“The crude mortality at the end of six months (primary end point) was 26 percent in the enalapril group and 44 percent in the placebo group--a reduction of 40 percent (P = 0.002).”
Panel auditInternal validity: high · scope of inference: Severe congestive heart failure, NYHA functional class IV.Key limitations: ejection fraction not reported in abstract · small sample · severe-HF subset only
There is no placebo arm; enalapril was the reference and was out-performed by ARNI, which does not establish whether ACEi/ARBs reduce mortality versus no RAS inhibition.
Panel auditInternal validity: high · scope of inference: HFrEF (EF <=40%, NYHA II-IV) comparing ARNI with enalapril.Key limitations: no placebo/untreated comparator for ACEi · enalapril is the loser arm, not a test of ACEi efficacy
4 of 27 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Independent randomised placebo-controlled trials directly demonstrate mortality reduction for both drug classes in HFrEF, with consistent corroborating real-world data.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent ARB-versus-placebo mortality trial in chronic HFrEF. Direct ARB placebo-controlled mortality evidence rests on the single CHARM programme [13] with a modest, barely significant effect, so the ARB limb is the weaker leg of the claim. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-blind placebo-controlled trial of an ARB in chronic HFrEF powered for all-cause mortality, in patients unable to tolerate ACE inhibitors.
Open question: Does an ARB reduce all-cause mortality versus placebo in chronic HFrEF independently of the candesartan CHARM programme? Why it is still open: The only direct ARB-versus-placebo mortality evidence in the corpus is CHARM [13], and it is modest (HR 0.88, P=0.018); VALIANT [3] has no placebo arm.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19